HC Wainwright Forecasts enGene’s Q1 Earnings (NASDAQ:ENGN)

enGene Holdings Inc. (NASDAQ:ENGN) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for enGene in a research note issued on Monday, December 23rd. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.41) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for enGene’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.37 EPS.

Other analysts also recently issued reports about the company. JMP Securities reiterated a “market outperform” rating and set a $18.00 target price on shares of enGene in a research report on Monday. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Raymond James initiated coverage on shares of enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. Morgan Stanley reiterated an “overweight” rating and set a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Finally, Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, enGene has an average rating of “Buy” and an average price target of $29.78.

enGene Trading Up 6.0 %

Shares of NASDAQ:ENGN opened at $6.32 on Wednesday. The business’s 50 day simple moving average is $8.05 and its 200 day simple moving average is $7.77. enGene has a 1 year low of $4.42 and a 1 year high of $18.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The company has a market capitalization of $279.45 million, a P/E ratio of -10.90 and a beta of -0.78.

enGene (NASDAQ:ENGN) last announced its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06.

Hedge Funds Weigh In On enGene

Hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. boosted its holdings in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares during the last quarter. SR One Capital Management LP acquired a new position in shares of enGene in the 2nd quarter worth approximately $4,715,000. Logos Global Management LP boosted its stake in shares of enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares during the last quarter. Franklin Resources Inc. increased its position in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after buying an additional 389,918 shares during the period. Finally, Wolverine Asset Management LLC bought a new position in enGene during the third quarter worth $37,000. 64.16% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $57,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Growth Opportunities F. Forbion bought 41,639 shares of the business’s stock in a transaction on Friday, September 27th. The shares were bought at an average cost of $5.97 per share, for a total transaction of $248,584.83. Following the completion of the acquisition, the insider now directly owns 2,059,459 shares in the company, valued at approximately $12,294,970.23. This trade represents a 2.06 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 420,965 shares of company stock worth $2,651,103. Insiders own 13.70% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.